AC
Publications
381
Views
119,398
Downloads
38,275
Supervised works
2
Items per page
1 - 381 of 381
Title Published in Access level OA Policy Year Views Downloads
Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort : a prospective observational cohort studyThe lancet. HIV
accessLevelRestricted
2024 48 0
Infectious disease events in people with HIV receiving kidney transplantation : Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort StudyBMC infectious diseases
accessLevelPublic
2024 11 7
Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV) : a multicenter, international, non-randomized clinical trial study protocolBMC infectious diseases
accessLevelPublic
2024 42 23
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIVClinical pharmacology and therapeutics
accessLevelPublic
2024 37 11
Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3)The journal of infectious diseases
accessLevelPublic
2024 330 272
Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1Journal of antimicrobial chemotherapy
accessLevelRestricted
2023 39 0
Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral TherapyClinical infectious diseases
accessLevelPublic
2023 66 26
Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV) : A Study Combining Modelling and Swiss HIV Cohort DataClinical infectious diseases
accessLevelPublic
2023 75 24
Viral suppression and retention in HIV care during the postpartum period among women living with HIV : a longitudinal multicenter cohort studyThe Lancet regional health. Europe
accessLevelPublic
2023 27 7
VIH : zoom sur les traitements injectables à longue durée d’actionRevue médicale suisse
accessLevelPublic
2023 62 39
Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor‐containing regimenBritish journal of clinical pharmacology
accessLevelPublic
2023 72 20
Mpox in people with advanced HIV infection: a global case seriesLancet
accessLevelPublic
2023 55 46
External validation of the Dat'AIDS score : A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or olderHIV medicine
accessLevelPublic
2023 65 26
Low prevalence of asymptomatic mpox in populations at high riskThe Lancet microbe
accessLevelPublic
2023 92 12
An Automated Literature Review Tool (LiteRev) for Streamlining and Accelerating Research Using Natural Language Processing and Machine Learning: Descriptive Performance Evaluation StudyJMIR. Journal of medical internet research
accessLevelPublic
2023 102 41
Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-studyBMC pharmacology & toxicology
accessLevelPublic
2023 36 22
Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV CoinfectionClinical infectious diseases
accessLevelRestricted
2023 90 0
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trialCritical care
accessLevelPublic
2023 51 22
Incidence of sexually transmitted infections and association with behavioural factors: Time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohortHIV medicine
accessLevelPublic
2023 59 26
Comparison of five different risk scores to predict incident type 2 diabetes in the Swiss HIV cohort studyAIDS
accessLevelPublic
2023 78 18
Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV : The Swiss HIV Cohort StudyThe Journal of infectious diseases
accessLevelPublic
2023 57 14
Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2)Open forum infectious diseases
accessLevelPublic
2023 36 23
Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus (HIV) in SwitzerlandClinical infectious diseases
accessLevelPublic
2023 64 13
A Case of Mpox ReinfectionClinical infectious diseases
accessLevelPublic
2023 35 38
No time for complacency on COVID-19 in EuropeLancet
accessLevelPublic
2023 100 19
The international Unity study for antivirals against mpox is a blueprint for future epidemicsNature medicine
accessLevelRestricted
2023 91 0
Triggers of change in sexual behavior among people with HIV: The Swiss U = U statement and Covid-19 comparedThe journal of infectious diseases
accessLevelPublic
2023 74 38
Does menopause transition influence viral suppression and adherence in women living with HIV?Journal of acquired immune deficiency syndromes
accessLevelPublic
2023 46 8
Multicentric evaluation of a specific intrathecal anti-Treponema pallidum IgG index as a diagnostic biomarker of neurosyphilis: results from a retro-prospective case–control studySexually transmitted infections
accessLevelRestricted
2023 115 0
Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons With Human Immunodeficiency Virus (HIV): The Swiss HIV Cohort StudyClinical infectious diseases
accessLevelPublic
2023 65 14
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2 : Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)Open forum infectious diseases
accessLevelPublic
2023 67 23
Sexual Behaviour and STI Incidence in Sexually Active MSM Living With HIV in Times of COVID-19Open forum infectious diseases
accessLevelPublic
2023 73 25
Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018The journal of antimicrobial chemotherapy
accessLevelPublic
2023 76 68
Effect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trialThrombosis research
accessLevelPublic
2023 270 40
SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant RecipientsVaccines
accessLevelPublic
2023 60 35
Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS)HIV medicine
accessLevelPublic
2022 101 60
Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trialTrials
accessLevelPublic
2022 71 16
Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variantsFrontiers in microbiology
accessLevelPublic
2022 223 22
Cardiovascular risk assessment in people living with HIV compared to the general populationEuropean journal of preventive cardiology
accessLevelPublic
2022 182 65
Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected IndividualsFrontiers in immunology
accessLevelPublic
2022 200 63
Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 EpidemicsJournal of acquired immune deficiency syndromes
accessLevelPublic
2022 126 31
An Approach to Quantifying the Interaction between Behavioral and Transmission ClustersViruses
accessLevelPublic
2022 70 10
CD4:CD8 Ratio and CD8 Cell Count and Their Prognostic Relevance for Coronary Heart Disease Events and Stroke in Antiretroviral Treated Individuals: The Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelPublic
2022 56 18
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in SwitzerlandPharmaceutics
accessLevelPublic
2022 39 17
Immunocompromised patients have been neglected in COVID-19 trials: a call for actionClinical microbiology and infection
accessLevelPublic
2022 35 32
Female Genital Mutilation/Cutting in the Swiss HIV Cohort Study: A Cross-Sectional StudyJournal of immigrant and minority health
accessLevelPublic
2022 61 34
La variole du singe: Une nouvelle épidémie – réponses aux questions fréquentes dans la pratiquePrimary and Hospital Care
accessLevelPublic
2022 169 48
A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimabLancet. Infectious diseases
accessLevelPublic
2022 84 99
Impact of Latent Tuberculosis on DiabetesThe journal of infectious diseases
accessLevelRestricted
2022 156 0
Accelerating investigation of new HIV drugs in pregnancy : advancing the research agenda from theory to actionJournal of the International AIDS Society
accessLevelPublic
2022 37 8
Use of Ritonavir-Boosted Nirmatrelvir in PregnancyClinical infectious diseases
accessLevelPublic
2022 73 14
Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension periodAIDS
accessLevelPublic
2022 698 119
Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe HypoxemiaJAMA
accessLevelRestricted
2022 143 0
How mHealth Can Contribute to Improving the Continuum of Care: A Scoping Review Approach to the Case of Human Immunodeficiency Virus in Sub-Saharan AfricaPublic health reviews
accessLevelPublic
2022 62 12
Transfer of antiretroviral drugs into breastmilk : a prospective study from the Swiss Mother and Child HIV Cohort StudyJournal of antimicrobial chemotherapy
accessLevelPublic
2022 58 26
A Systematic Molecular Epidemiology Screen Reveals Numerous Human Immunodeficiency Virus (HIV) Type 1 Superinfections in the Swiss HIV Cohort StudyThe journal of infectious diseases
accessLevelRestricted
2022 80 0
Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trialsAIDS
accessLevelRestricted
2022 34 0
How the COVID-19 Pandemic Alters the Landscapes of the HIV and Tuberculosis Epidemics in South Africa: A Case Study and Future DirectionsEpidemiologia
accessLevelPublic
2022 60 43
VIH et Covid-19 : deux pandémies virales en interactionRevue médicale suisse
accessLevelPublic
2022 50 31
Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trialClinical and translational science
accessLevelPublic
2022 110 57
Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort studyThe journal of antimicrobial chemotherapy
accessLevelRestricted
2022 64 0
Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trialResearch and practice in thrombosis and haemostasis
accessLevelPublic
2022 198 198
Anticholinergic and sedative medications are associated with neurocognitive performance of well treated people with human immunodeficiency virusOpen forum infectious diseases
accessLevelPublic
2022 44 29
Facilitators and barriers of women's participation in HIV clinical research in Switzerland: A qualitative studyHIV medicine
accessLevelPublic
2022 279 97
Quantifying and predicting ongoing Human Immunodeficiency Virus Type 1 (HIV-1) transmission dynamics in Switzerland using a distance-based clustering approachThe journal of infectious diseases
accessLevelRestricted
2022 99 2
A highly virulent variant of HIV-1 circulating in the NetherlandsScience
accessLevelPublic
2022 145 26
Bas les masques, et après ?Revue médicale suisse
accessLevelPublic
2022 31 20
Risk Factors and Incidence of Sexually Transmitted Infections in the Swiss HIV Cohort StudyOpen forum infectious diseases
accessLevelPublic
2022 109 55
Decreasing incidence and determinants of Bacterial Pneumonia in people with HIV: The Swiss HIV Cohort StudyThe Journal of infectious diseases
accessLevelPublic
2022 101 80
Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patientsBMC infectious diseases
accessLevelPublic
2022 104 56
Decrease of condom use in heterosexual couples and its impact on pregnancy rates: the Swiss HIV Cohort Study (SHCS)HIV medicine
accessLevelPublic
2022 78 24
Cohort Profile Update: The Swiss HIV Cohort Study (SHCS)International journal of epidemiology
accessLevelRestricted
2022 159 0
Approaches to accelerating the study of new antiretrovirals in pregnancyJournal of the International AIDS Society
accessLevelPublic
2022 38 45
Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trialBritish journal of clinical pharmacology
accessLevelRestricted
2021 169 0
Cyber harassment of female scientists will not be the new normThe Lancet Infectious Diseases
accessLevelPublic
2021 208 174
Network Analysis of Outpatients to Identify Predictive Symptoms and Combinations of Symptoms Associated With Positive/Negative SARS-CoV-2 Nasopharyngeal SwabsFrontiers in Medicine
accessLevelPublic
2021 187 96
Predicting, Diagnosing, and Treating Acute and Early HIV Infection in a Public Sector Facility in EswatiniJournal of acquired immune deficiency syndromes
accessLevelPublic
2021 127 77
Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIVClinical infectious diseases
accessLevelRestricted
2021 141 0
Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort StudyOpen Forum Infectious Diseases
accessLevelPublic
2021 233 117
Effect of Rosuvastatin Therapy on Biomarkers of Inflammation and Immune Activation in People With Human Immunodeficiency Virus at Intermediate Cardiovascular RiskThe journal of infectious diseases
accessLevelRestricted
2021 171 9
Kaposi sarcoma in antiretroviral therapy-treated people with HIV: a wake-up call for research on human herpesvirus-8AIDS
accessLevelPublic
2021 210 138
Predictors of virological failure and time to viral suppression of first-line integrase inhibitor-based antiretroviral treatmentClinical infectious diseases
accessLevelPublic
2021 148 75
The role of Human Immunodeficiency Virus (HIV) asymptomatic status when starting antiretroviral therapy on adherence and treatment outcomes and implications for test and treat: the swiss HIV Cohort StudyClinical Infectious Diseases
accessLevelRestricted
2021 129 0
VIH/sida - VIH au temps du Covid-19 : rencontre de deux pandémiesRevue médicale suisse
accessLevelPublic
2021 173 65
Nouveautés dans le diagnostic du VIHForum médical suisse
accessLevelPublic
2021 220 164
Caring for people living with HIV during the global coronavirus disease 2019 pandemicAIDS
accessLevelRestricted
2021 193 0
Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort StudyHIV medicine
accessLevelRestricted
2021 259 0
Alcohol consumption and neurocognitive deficits in people with well-treated HIV in SwitzerlandPloS one
accessLevelPublic
2021 172 266
Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIVAIDS
accessLevelPublic
2021 152 58
Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxisNature communications
accessLevelPublic
2021 52 6
Weight gain stopping/switch rules for antiretroviral clinical trialsAIDS
accessLevelPublic
2021 144 43
Prophylaxis for COVID-19: a systematic reviewClinical microbiology and infection
accessLevelPublic
2021 62 33
Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequityThe journal of antimicrobial chemotherapy
accessLevelRestricted
2021 132 0
Identifying and characterizing trans women in the swiss HIV Cohort Study as an epidemiologically distinct risk groupClinical Infectious Diseases
accessLevelRestricted
2021 136 0
Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized TrialEClinicalMedicine
accessLevelPublic
2021 578 112
Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort StudyAnnals of internal medicine
accessLevelRestricted
2021 142 0
Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase InhibitorsClinical infectious diseases
accessLevelRestricted
2021 132 0
Representations and Willingness of People Living With HIV in Switzerland to Participate in HIV Cure Trials: The Case of Gene-Modified Cell TherapiesJournal of acquired immune deficiency syndromes
accessLevelRestricted
2021 116 0
Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort StudyThe journal of infectious diseases
accessLevelPublic
2021 74 13
Impact of rosuvastatin on atherosclerosis in people with hiv at moderate cardiovascular risk: a randomised, controlled trialAIDS
accessLevelPublic
2021 605 125
Clinical outcomes of 2-drug regimens vs 3-drug regimens in antiretroviral treatment-experienced people living with Human Immunodeficiency VirusClinical infectious diseases
accessLevelPublic
2021 115 83
The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort StudyJournal of clinical medicine
accessLevelPublic
2021 49 24
Possible link between anosmia and COVID-19: sniffing out the truthEuropean Archives of Oto-Rhino-Laryngology
accessLevelPublic
2020 157 137
Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study : 1980-2018Antiviral therapy
accessLevelRestricted
2020 33 0
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelinesThe Lancet HIV
accessLevelPublic
2020 170 76
Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristicsAmerican Heart Journal
accessLevelPublic
2020 196 82
Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort StudyClinical Infectious Diseases
accessLevelRestricted
2020 195 0
Clinicopathologic Aspects of a Papulovesicular Eruption in a Patient With COVID-19JAMA Dermatology
accessLevelRestricted
2020 280 0
Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK StudyJournal of the American College of Cardiology
accessLevelPublic
2020 363 95
Buyers' club : une alternative pour l'accès au traitement ?Revue médicale suisse
accessLevelPublic
2020 348 134
Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort StudyThe journal of infectious diseases
accessLevelPublic
2020 153 115
Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIVPLoS biology
accessLevelPublic
2020 61 16
Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costsSwiss Medical Weekly
accessLevelPublic
2020 399 283
Towards the real-time inclusion of sex- and age-disaggregated data in pandemic responsesBMJ global health
accessLevelPublic
2020 54 15
Mycobaterium fortuitum disseminated infection in an immunocompetent patient without predisposing factorsBMJ case reports
accessLevelRestricted
2020 138 0
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trialPLoS medicine
accessLevelPublic
2020 158 110
Macrophage activation syndrome as an unusual presentation of paucisymptomatic severe acute respiratory syndrome coronavirus 2 infection: A case reportMedicine (Baltimore)
accessLevelPublic
2020 345 112
HIV and antiretroviral therapy-related fat alterationsNature Reviews. Disease Primers
accessLevelRestricted
2020 171 20
The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profileHIV Medicine
accessLevelPublic
2020 356 164
Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysisEClinicalMedicine
accessLevelPublic
2020 71 16
First reported case of Rothia dentocariosa spondylodiscitis in an immunocompetent patientIDCases
accessLevelPublic
2020 464 174
How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?HIV medicine
accessLevelPublic
2020 80 14
Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral TherapyOpen Forum Infectious Diseases
accessLevelPublic
2020 179 96
Longitudinal Progression of Subclinical Coronary Atherosclerosis in Swiss HIV-Positive Compared With HIV-Negative Persons Undergoing Coronary Calcium Score Scan and CT AngiographyOpen forum infectious diseases
accessLevelPublic
2020 94 65
Heritability of the HIV-1 reservoir size and decay under long-term suppressive ARTNature Communications
accessLevelPublic
2020 203 46
Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patientsClinical Infectious Diseases
accessLevelRestricted
2020 302 3
C-terminus apoa-1 mimetic peptides to detect cognate auto-antibodies and reverse HIV-induced foam cell formationAtherosclerosis
accessLevelRestricted
2020 208 0
Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19 : initial assessmentJournal of the International AIDS Society
accessLevelPublic
2020 40 7
Dexamethasone and remdesivir: finding method in the COVID-19 madnessThe Lancet microbe
accessLevelPublic
2020 194 21
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort SettingJournal of Acquired Immune Deficiency Syndromes
accessLevelPublic
2020 165 64
Cobicistat : A case of mislabelled drug-drug interaction risk?British journal of clinical pharmacology
accessLevelPublic
2020 43 11
Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trialBMJ Open
accessLevelPublic
2020 210 94
VIH: prévention, traitement et perspectivesRevue médicale suisse
accessLevelPublic
2020 319 153
Impact of the M184V/I Mutation on the efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV treatment-experienced patientsOpen Forum Infectious Diseases
accessLevelPublic
2019 259 212
Next-Generation Sequencing for the Diagnosis of Challenging Culture-Negative EndocarditisFrontiers in Medicine
accessLevelPublic
2019 351 207
Female Genital Schistosomiasis and HIV: Research Urgently Needed to Improve Understanding of the Health Impacts of This Important CoinfectionJournal of acquired immune deficiency syndromes
accessLevelRestricted
2019 149 0
Exploring the Patterns of Use and Acceptability of Mobile Phones Among People Living With HIV to Improve Care and Treatment: Cross-Sectional Study in Three Francophone West African CountriesJMIR mhealth and uhealth
accessLevelPublic
2019 130 40
Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohortAtherosclerosis
accessLevelRestricted
2019 390 1
Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against OsteoporosisOsteoporosis International
accessLevelRestricted
2019 311 1
Nouveautés dans le dépistage, la prévention et la prise en charge du VIH en 2018Revue médicale suisse
accessLevelPublic
2019 36 9
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trialsLancet
accessLevelRestricted
2019 47 0
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling studyThe lancet. HIV.
accessLevelPublic
2019 42 24
Reply to “Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Comment on: Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis” by S. Noe, H. Jaeger, E. WolfOsteoporosis international
accessLevelRestricted
2019 34 0
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherenceThe journal of antimicrobial chemotherapy
accessLevelRestricted
2019 57 0
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1New England Journal of Medicine
accessLevelPublic
2019 246 86
Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017Journal of the International AIDS society
accessLevelPublic
2019 334 131
A systematic phylogenetic approach to study the interaction of HIV-1 with coinfections, noncommunicable diseases, and opportunistic diseasesThe Journal of Infectious Diseases
accessLevelRestricted
2019 278 0
Why do sub‐Saharan Africans present late for HIV care in Switzerland ?HIV medicine
accessLevelRestricted
2019 51 0
Viral diversity based on next-generation sequencing of HIV-1 provides precise estimates of infection recency and time since infectionThe Journal of Infectious Diseases
accessLevelRestricted
2019 246 0
Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohortBMC infectious diseases
accessLevelPublic
2019 170 46
Non-AIDS defining malignancies in the combination ART era: immunological and socio-behavioral risk factorsF1000Research
accessLevelPublic
2019 200 78
Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active MetabolitesClinical Pharmacokinetics
accessLevelPublic
2018 604 630
Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysisF1000Research
accessLevelPublic
2018 100 52
Aging and the evolution of comorbidities among HIV-positive individuals in a European cohortAIDS
accessLevelRestricted
2018 141 0
Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort StudyLiver International
accessLevelRestricted
2018 437 0
Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patientsJournal of Infection
accessLevelRestricted
2018 506 1
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimensHIV Medicine
accessLevelPublic
2018 320 144
Expert consensus statement on the science of HIV in the context of criminal lawJournal of the International AIDS Society
accessLevelPublic
2018 92 16
Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort StudyVirus Evolution
accessLevelPublic
2018 306 75
High Rates of Subsequent Asymptomatic Sexually Transmitted Infections and Risky Sexual Behavior in Patients Initially Presenting With Primary Human Immunodeficiency Virus-1 InfectionClinical Infectious Diseases
accessLevelRestricted
2018 361 0
A buyers' club to improve access to hepatitis C treatment for vulnerable populationsSwiss Medical Weekly
accessLevelPublic
2018 1,156 405
Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination ScheduleClinical infectious diseases
accessLevelRestricted
2018 49 0
Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID StudyKidney International Reports
accessLevelPublic
2018 419 146
Traitements antirétroviraux : vers un allègement ?Revue médicale suisse
accessLevelPublic
2018 32 28
The cumulative impact of harm reduction on the swiss HIV epidemic: cohort study, mathematical model, and phylogenetic analysisOpen Forum Infectious Diseases
accessLevelPublic
2018 278 87
Universal test and treat is not associated with sub‐optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trialJournal of the International AIDS Society
accessLevelPublic
2018 101 17
Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite PathogenicityMolecular Biology and Evolution
accessLevelPublic
2018 458 179
Will NNRTIs be driving forward again ?The lancet. HIV
accessLevelRestricted
2018 33 0
Extracavitary primary effusion lymphoma (PEL) presenting as bilateral adrenal gland involvement in an HIV-positive patientAnnals of Hematology
accessLevelRestricted
2018 345 0
Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO studyHIV Medicine
accessLevelPublic
2018 289 89
Time to overcome pretreatment HIV drug resistanceThe Lancet Infectious Diseases
accessLevelPublic
2018 366 200
Managing Advanced HIV Disease in a Public Health ApproachClinical infectious diseases
accessLevelPublic
2018 35 18
Evaluation of the Xpert MTB/RIF assay for the diagnosis of smear-negative pulmonary and extrapulmonary tuberculosis in MadagascarInternational journal of infectious diseases
accessLevelPublic
2018 155 71
Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?HIV Medicine
accessLevelRestricted
2018 337 0
Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in SwitzerlandHIV Medicine
accessLevelRestricted
2018 514 0
Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative personsEuropean heart journal
accessLevelRestricted
2018 71 0
The Persistent Challenge of Advanced HIV Disease and AIDS in the Era of Antiretroviral TherapyClinical infectious diseases
accessLevelPublic
2018 31 5
Anti-inflammatory therapy in well controlled HIV infectionThe Lancet HIV
accessLevelRestricted
2018 398 0
Benefits and risks of rapid initiation of antiretroviral therapyAIDS
accessLevelPublic
2018 410 246
Tracing HIV-1 strains that imprint broadly neutralizing antibody responsesNature
accessLevelRestricted
2018 125 0
Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activityThe Journal of experimental medicine
accessLevelPublic
2018 267 98
Universal test and treat and the HIV epidemic in rural South Africa : a phase 4, open-label, community cluster randomised trialThe lancet. HIV
accessLevelPublic
2018 37 24
Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretroviralsMedicine (Philadelphia)
accessLevelPublic
2017 363 157
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general populationAIDS
accessLevelPublic
2017 371 160
Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysiseLife
accessLevelPublic
2017 460 171
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysisThe Lancet HIV
accessLevelRestricted
2017 408 0
Bone health in HIV and hepatitis B or C infectionsTherapeutic advances in musculoskeletal disease
accessLevelPublic
2017 472 266
Hepatitis delta-associated mortality in HIV/HBV-coinfected patientsJournal of Hepatology
accessLevelPublic
2017 368 410
CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European studyJournal of Antimicrobial Chemotherapy
accessLevelRestricted
2017 363 0
Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort StudyHIV Medicine
accessLevelRestricted
2017 350 0
High prevalence of physical inactivity among patients from the Swiss HIV Cohort StudyAIDS Care
accessLevelPublic
2017 354 507
Human papillomavirus antibody response following HAART initiation among MSMAIDS
accessLevelRestricted
2017 384 0
Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort StudyClinical Infectious Diseases
accessLevelRestricted
2017 344 0
Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort AnalysisClinical Infectious Diseases
accessLevelPublic
2017 357 167
Adverse events of raltegravir and dolutegravirAIDS
accessLevelPublic
2017 385 152
Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP)The Lancet HIV
accessLevelRestricted
2017 350 0
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort studyBMC Infectious Diseases
accessLevelPublic
2017 384 160
Blinded by Zika? A missed HIV diagnosis that resulted in optic neuropathy and blindness: a case reportBMC Research Notes
accessLevelPublic
2017 368 159
Mining for pairs: shared clinic visit dates identify steady HIV-positive partnershipsHIV Medicine
accessLevelRestricted
2017 399 0
Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort StudyOpen Forum Infectious Diseases
accessLevelPublic
2017 364 139
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trialThe Lancet HIV
accessLevelRestricted
2017 363 0
Impact of screening and antiretroviral therapy on anal cancer incidence in HIV-positive MSMAIDS
accessLevelPublic
2017 553 315
The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular EventsJournal of acquired immune deficiency syndromes
accessLevelRestricted
2016 51 0
Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy : The Swiss HIV Cohort StudyOpen forum infectious diseases
accessLevelPublic
2016 52 12
Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland comparedInternational journal of infectious diseases
accessLevelPublic
2016 467 139
Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventionsHepatology
accessLevelPublic
2016 660 220
Hepatitis C Virus Awareness Among Men Who Have Sex With Men in Southwest SwitzerlandSexually transmitted diseases
accessLevelRestricted
2016 39 0
Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence CountryJournal of Clinical Microbiology
accessLevelRestricted
2016 478 0
HIV-Positive-to-HIV-Positive Liver TransplantationAmerican journal of transplantation
accessLevelPublic
2016 601 371
Determinants of HIV-1 broadly neutralizing antibody inductionNature Medicine
accessLevelPublic
2016 501 392
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort StudyThe Journal of Infectious Diseases
accessLevelPublic
2016 383 197
Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV InfectionThe journal of infectious diseases
accessLevelRestricted
2016 39 0
The 2014–2015 Ebola outbreak in West Africa: Hands OnAntimicrobial Resistance and Infection Control
accessLevelPublic
2016 476 218
Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort AnalysisClinical Infectious Diseases
accessLevelRestricted
2016 631 1
HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort StudyClinical Infectious Diseases
accessLevelPublic
2016 462 145
Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and reviewNew microbes and new infections
accessLevelRestricted
2015 575 1
Increases in Condomless Sex in the Swiss HIV Cohort StudyOpen forum infectious diseases
accessLevelPublic
2015 62 17
Corrigendum to "Dolutegravir-based antiretroviral therapy in a severely overweight child with a multi-drug resistant human immunodeficiency virus infection. A case report and review" [New Microbes New Infect] 6 (2015) 1-4]New microbes and new infections
accessLevelRestricted
2015 462 0
Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort StudyBMC infectious diseases
accessLevelPublic
2015 64 18
Hit me with your best shot: dolutegravir - a space in the next WHO guidelines ?AIDS
accessLevelRestricted
2015 47 0
Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in SwitzerlandAIDS
accessLevelRestricted
2015 62 0
Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents : a systematic reviewClinical infectious diseases
accessLevelRestricted
2015 51 0
Is monotherapy maintenance the way forward ?The lancet. HIV
accessLevelPublic
2015 44 14
Reasons for late presentation to HIV care in SwitzerlandJournal of the International AIDS Society
accessLevelPublic
2015 50 11
Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelPublic
2015 73 15
Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisalBMC public health
accessLevelPublic
2015 55 5
Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective studyEuropean journal of clinical investigation
accessLevelPrivate
2015 568 0
The future role of CD4 cell count for monitoring antiretroviral therapyLancet. Infectious diseases
accessLevelRestricted
2015 456 0
Prise en charge du VIH/sida en 2015Revue médicale suisse
accessLevelPublic
2015 52 20
HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected personsBMC gastroenterology
accessLevelPublic
2015 43 7
Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in AfricaAIDS
accessLevelPublic
2015 58 28
Evidence on the protective role of high-density lipoprotein (HDL) in HIV-infected individualsCurrent vascular pharmacology
2015 641 0
Syphilis: Diagnostik und BehandlungSwiss Medical Forum
accessLevelPublic
2015 320 562
Generating Evidence to Improve the Response to Neglected Diseases : How Operational Research in a Médecins Sans Frontières Buruli Ulcer Treatment Programme Informed International Management GuidancePLoS neglected tropical diseases
accessLevelPublic
2015 53 7
World Health Organization Guidelines on Postexposure Prophylaxis for HIV : Recommendations for a Public Health ApproachClinical infectious diseases
accessLevelRestricted
2015 41 0
Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortalityAIDS
accessLevelRestricted
2015 51 0
Hyaluronic Acid Filler in HIV-Associated Facial Lipoatrophy: Evaluation of Tissue Distribution and Morphology with MRIDermatology
accessLevelRestricted
2015 721 1
Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General PopulationOpen forum infectious diseases
accessLevelPublic
2015 538 221
Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disordersAIDS research and therapy
accessLevelPublic
2015 575 296
Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCVInternational journal of epidemiology
accessLevelPublic
2014 689 410
Disentangling human tolerance and resistance against HIVPLoS biology
accessLevelPublic
2014 592 314
Clinical significance of the CCR5delta32 allele in hepatitis CPloS one
accessLevelPublic
2014 517 201
The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patientsAIDS
accessLevelRestricted
2014 482 0
Haemophagocytic syndrome and elevated EBV load as initial manifestation of Hodgkin lymphoma in a HIV patient: case report and review of the literatureJournal of the International AIDS Society
accessLevelPublic
2014 549 437
AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to beJournal of the International AIDS Society
accessLevelPublic
2014 576 250
Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patientsAIDS
accessLevelRestricted
2014 531 0
Systematic review and meta-analysis: Patient and programme impact of fixed-dose combination antiretroviral therapyTM & IH. Tropical medicine and international health
accessLevelPublic
2014 559 460
Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort StudyClinical infectious diseases
accessLevelRestricted
2014 657 0
Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activityAIDS research and therapy
accessLevelPublic
2014 659 914
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysisAIDS
accessLevelRestricted
2014 456 0
Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in ZambiaClinical infectious diseases
accessLevelPublic
2014 683 238
Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in SwitzerlandAmerican journal of epidemiology
accessLevelPublic
2014 808 30
Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wideThe Journal of infectious diseases
accessLevelRestricted
2014 541 0
Lipohypertrophy and metabolic disorders in HIV patients on antiretroviral therapy: a systematic multidisciplinary clinical approachJournal of the International AIDS Society
accessLevelPublic
2014 584 1,365
Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backboneHIV clinical trials
accessLevelRestricted
2014 51 0
Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort StudyAntimicrobial agents and chemotherapy
accessLevelPublic
2014 835 428
Impact of human immunodeficiency virus on the severity of buruli ulcer disease: results of a retrospective study in cameroonOpen forum infectious diseases
accessLevelPublic
2014 480 283
Microstructural alterations of trabecular and cortical bone in long-term HIV-infected elderly men on successful antiretroviral therapyAIDS
accessLevelPublic
2014 755 552
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatmentAntimicrobial agents and chemotherapy
accessLevelRestricted
2014 74 0
Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysisAIDS
accessLevelRestricted
2014 493 2
Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort StudyOpen forum infectious diseases
accessLevelPublic
2014 942 333
Réplication cérébrale du VIH malgré une thérapie antirétrovirale efficace: impact clinique et prise en chargeRevue médicale suisse
accessLevelPublic
2014 648 291
Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infectionThe American journal of cardiology
accessLevelRestricted
2013 569 0
Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence : the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa : study protocol for a cluster randomised controlled trialTrials
accessLevelPublic
2013 63 5
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infectionThe Journal of infectious diseases
accessLevelRestricted
2013 602 0
Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysisAIDS
accessLevelRestricted
2013 519 0
HIV-infected women in Europe: gender-specific needs and challengesAntiviral therapy
2013 577 0
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort StudyAmerican journal of epidemiology
accessLevelRestricted
2013 596 0
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysisAIDS
accessLevelRestricted
2013 566 0
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort StudyHIV medicine
accessLevelRestricted
2013 578 0
Clinical Course and Management of Iatrogenic Cushing's Syndrome after Co-Administration of Injected-Triamcinolone and Ritonavir: a Systematic ReviewJournal of Antivirals and Antiretrovirals
accessLevelPublic
2013 1,187 226
Les os des personnes infectées par le VIH sont-ils si fragiles?Revue médicale suisse
accessLevelRestricted
2013 575 0
The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patientsPLoS computational biology
accessLevelPublic
2013 645 236
HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosisPLOS genetics
accessLevelPublic
2013 881 611
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individualsPharmacogenetics and genomics
accessLevelRestricted
2013 574 0
Intracranial hypertension following highly active antiretroviral therapy interruption in an HIV-infected woman: case report and review of the literatureAIDS
accessLevelRestricted
2013 598 0
La prophylaxie postexposition dans tous ses étatsRevue médicale suisse
accessLevelRestricted
2013 561 0
VIH/sida : une sélection des nouveautés les plus prometteuses en 2012Revue médicale suisse
accessLevelRestricted
2013 510 2
Long-term HIV infection and antiretroviral therapy are associated with bone microstructure alterations in premenopausal womenOsteoporosis international
accessLevelPublic
2013 783 274
Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot studyNeurology
accessLevelRestricted
2013 690 1
Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort StudyPloS one
accessLevelPublic
2013 549 547
Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS)Journal of acquired immune deficiency syndromes
accessLevelRestricted
2013 549 0
Pulmonary embolism and iatrogenic Cushing's syndrome after co-administration of injected-triamcinolone and ritonavirAIDS
accessLevelPublic
2013 511 288
Association of Alcohol Consumption and HIV Surrogate Markers in Participants of the Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelRestricted
2013 521 0
Bénéfices d'un accompagnement psychologique des patients vivant avec le VIHRevue médicale suisse
accessLevelRestricted
2013 679 0
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trialLancet. Infectious diseases
accessLevelRestricted
2013 596 0
Micro-Structural Brain Alterations in Aviremic HIV+ Patients with Minor Neurocognitive Disorders: A Multi-Contrast Study at High FieldPloS one
accessLevelPublic
2013 685 1,130
Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort studyThe Journal of infectious diseases
accessLevelRestricted
2013 595 0
Produits de comblement du visage : dispositifs médicaux ou médicaments ? Implication pour les patients VIH+ atteints de lipoatrophieRevue médicale suisse
accessLevelRestricted
2012 564 0
Efavirenz is not a known teratogenThe Pediatric infectious disease journal
accessLevelRestricted
2012 522 0
Expert reviews: who are they for?Expert opinion on pharmacotherapy
accessLevelRestricted
2012 539 0
Preferred antiretroviral drugs for the next decade of scale upJournal of the International AIDS Society
accessLevelPublic
2012 494 424
Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infectionBritish journal of cancer
accessLevelPublic
2012 522 1,049
Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patientAIDS
accessLevelPublic
2012 582 516
Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settingsHIV/AIDS[1179-1373]
accessLevelPublic
2012 715 863
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavirAIDS
accessLevelRestricted
2012 579 0
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumoniaAIDS
accessLevelRestricted
2012 638 0
Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosisAntimicrobial agents and chemotherapy
accessLevelPublic
2012 834 1,171
Buruli et VIH: une interaction complexe et peu étudiéeRevue médicale suisse
accessLevelRestricted
2012 476 0
Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infectionJournal of clinical microbiology
accessLevelPublic
2012 937 1,631
Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccinePloS one
accessLevelPublic
2012 721 309
Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensPloS one
accessLevelPublic
2012 596 258
VIH/SIDARevue médicale suisse
accessLevelRestricted
2012 486 1
Outcome of smoking cessation counselling of HIV-positive persons by HIV care physiciansHIV medicine
accessLevelRestricted
2012 546 0
Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemicClinical infectious diseases
accessLevelRestricted
2012 509 0
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaborationInternational journal of epidemiology
accessLevelRestricted
2012 601 0
Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patientsHIV medicine
accessLevelRestricted
2012 673 0
Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelRestricted
2012 578 0
Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settingsBMC infectious diseases
accessLevelPublic
2012 574 432
Défis de la co-infection par le virus de l'hépatite C et le VIHRevue médicale suisse
accessLevelRestricted
2012 555 0
Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort StudyHIV medicine
accessLevelRestricted
2012 550 1
Viral load monitoring in resource-limited settings: a medical and public health priorityAIDS
accessLevelRestricted
2012 496 1
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patientsPloS one
accessLevelPublic
2012 592 216
Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011Clinical infectious diseases
accessLevelPublic
2012 584 546
Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infectionsAIDS
accessLevelPublic
2012 699 416
Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinicJournal of acquired immune deficiency syndromes
accessLevelRestricted
2011 48 0
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipientsHaematologica
accessLevelPublic
2011 980 566
Ageing with HIV : medication use and risk for potential drug-drug interactionsJournal of antimicrobial chemotherapy
accessLevelRestricted
2011 34 0
Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexualsWorld journal of gastroenterology
accessLevelPublic
2011 875 607
Successful efavirenz dose reduction guided by therapeutic drug monitoringAntiviral therapy
accessLevelRestricted
2011 25 0
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysisAIDS
accessLevelRestricted
2011 43 0
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center studyArthritis and rheumatism
accessLevelRestricted
2011 824 8
Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and SwitzerlandPloS one
accessLevelPublic
2011 1,222 350
Co-infection tuberculose et VIH: enjeux thérapeutiquesRevue médicale suisse
accessLevelRestricted
2011 611 0
Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients : The ACHIEV2E Collaboration Study GroupClinical infectious diseases
accessLevelRestricted
2011 67 0
VIH/SIDA : nombreuses nouveautésRevue médicale suisse
accessLevelPublic
2011 42 51
A randomized crossover study to compare efavirenz and etravirine treatmentAIDS
accessLevelRestricted
2011 78 0
Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settingsHIV/AIDS
accessLevelPublic
2011 691 515
The first decade of antiretroviral therapy in AfricaGlobalization and health
accessLevelPublic
2011 48 7
HIV treatment for preventionJournal of the International AIDS Society
accessLevelPublic
2011 47 12
Clinical relevance of cytomegalovirus viraemiaHIV medicine
accessLevelRestricted
2011 605 0
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteersAntimicrobial agents and chemotherapy
accessLevelRestricted
2010 589 0
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort StudyAntiviral therapy
2010 524 0
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavirPharmacogenetics and genomics
accessLevelRestricted
2010 624 0
Improving first-line antiretroviral therapy in resource-limited settingsCurrent opinion in HIV and AIDS
accessLevelRestricted
2010 526 0
Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohortsAIDS
accessLevelRestricted
2010 482 0
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infectionThe Journal of infectious diseases
accessLevelPublic
2010 582 281
Reduction of missed appointments at an urban primary care clinic: a randomised controlled studyBMC family practice
accessLevelPublic
2010 636 356
Treatment of HIV infection with drugs for HSV-2 infectionLancet
accessLevelRestricted
2010 488 0
Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort StudyBritish journal of cancer
accessLevelRestricted
2010 754 1
Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countriesJAMA
accessLevelRestricted
2010 546 0
Optimizing HIV drug therapy
accessLevelPublic
2010 622 1,806
High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapyHIV medicine
accessLevelRestricted
2010 573 0
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in CameroonBMC public health
accessLevelPublic
2010 593 240
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patientsAIDS
accessLevelRestricted
2010 552 0
Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemiaClinical infectious diseases
accessLevelRestricted
2010 558 0
Hyaluronic acid injections to fill facial lipoatrophy in the context of a lipodystrophy syndrome associated with HIVDermatologica Helvetica
accessLevelPublic
2010 202 39
No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trialHIV medicine
accessLevelRestricted
2010 540 0
Patient needs and point-of-care requirements for HIV load testing in resource-limited settingsThe Journal of infectious diseases
accessLevelRestricted
2010 545 0
Cognitive dysfunction in HIV patients despite long-standing suppression of viremiaAIDS
accessLevelRestricted
2010 881 1
When to start antiretroviral therapy in resource-limited settings: a human rights analysisBMC international health and human rights
accessLevelPublic
2010 586 319
Health perceptions of African HIV-infected patients and their physiciansPatient education and counseling
accessLevelRestricted
2010 574 0
A new era of antiretroviral drug toxicityAntiviral therapy
2009 538 0
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoringAIDS
accessLevelRestricted
2009 63 0
Education thérapeutique en maladie infectieuse : l'exemple de l'infection à VIHRevue médicale suisse
2009 588 0
HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trialAIDS
accessLevelRestricted
2009 619 0
Safety and efficacy of once-daily nevirapine dosing: a multicohort studyAntiviral therapy
2009 620 0
Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine : a nested case-control studyClinical infectious diseases
accessLevelRestricted
2009 40 0
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional studyThe Journal of infectious diseases
accessLevelRestricted
2009 555 0
Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patientsAntiviral therapy
accessLevelRestricted
2009 25 0
How developing world concerns need to be part of drug development plans: a case study of four emerging antiretroviralsDrug discovery today
accessLevelRestricted
2008 55 0
Dix ans de lipodystrophie (1998-2008) : un syndrome encore méconnuRevue médicale suisse
accessLevelPublic
2008 532 102
Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in CameroonJournal of acquired immune deficiency syndromes
accessLevelRestricted
2008 49 0
The marriage of science and optimized HIV care in resource-limited settingsAIDS
accessLevelRestricted
2008 35 0
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switchingAIDS
accessLevelRestricted
2008 52 0
Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapyHIV medicine
accessLevelRestricted
2008 50 0
Initial treatment for HIV infection--an embarrassment of richesThe New England journal of medicine
accessLevelRestricted
2008 571 0
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006HIV medicine
accessLevelRestricted
2008 568 0
10 Jahren Lipodystrophie (1998-2008): Die "Groupe Lipo" der Hôpitaux universitaires de Genève: Ein Beratungsangebot für VIH-Positive mit dem Lipodystrophie-SyndromeDermatologica Helvetica
accessLevelPublic
2008 197 27
Clinical update: adverse effects of antiretroviral therapyLancet
accessLevelRestricted
2007 593 0
HIV viral load monitoring in resource-limited regions: optional or necessary?Clinical infectious diseases
accessLevelRestricted
2007 583 1
Treating HIV in the developing world: getting ahead of the drug development curveDrug discovery today
accessLevelRestricted
2007 44 0
Generic fixed-dose combination antiretroviral treatment in resource-poor settings : multicentric observational cohortAIDS
accessLevelRestricted
2006 59 0
Field assessment of generic antiretroviral drugs : a prospective cohort study in CameroonAntiviral therapy
accessLevelRestricted
2005 56 0
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudineAIDS
accessLevelRestricted
2004 26 0
Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapyClinical infectious diseases
accessLevelRestricted
2004 49 0
First-line and second-line antiretroviral therapyLancet
accessLevelRestricted
2004 58 0
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trialLancet
accessLevelRestricted
2004 53 0
HIV drug resistanceNew England journal of medicine
accessLevelPublic
2004 33 19
Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapyAIDS
accessLevelRestricted
2003 513 0
Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans FrontièresAIDS
accessLevelRestricted
2003 38 0
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack